Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. Receive News & Ratings for Bellerophon Therapeutics Daily - Enter ...
Background Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic ...
We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at ...
PAH, or pulmonary hypertension, can leave someone breathless even after a short walk, but better drug combinations have ...
62% of patients had intermediate-high COMPERA 2.0 risk status, whereas at follow-up, 61% were intermediate-low or low risk.
If your walking speed is faster than your peers, you may be at a lower risk of metabolic conditions such as diabetes or ...
StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a research report released on Wednesday morning. The firm issued a hold rating on the biotechnology ...
In the era of DOACs, risk for CTEPH following pulmonary embolism is affected by multiple factors, including gender and heart load.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback